

October 24, 2022

TO: Saskatchewan Health Authority
Indigenous Services Canada- Saskatchewan Region
Northern Intertribal Health Authority
Saskatchewan Medical Association
College of Registered Nurses of Saskatchewan
Saskatchewan College of Pharmacy Professionals
Saskatchewan College of Paramedics
Saskatchewan College of Respiratory Therapists
College of Physicians and Surgeons of Saskatchewan
Registered Psychiatric Nurses Association of Saskatchewan

Dear Colleagues:

Re: Pfizer BioNTech's Monovalent COMIRNATY® 6 months – 4 years Vaccine Announcement

Starting **October 26, 2022**, Pfizer BioNTech's monovalent COMIRNATY® 6 months – 4 years vaccine (**maroon cap/label** 3 mcg/0.2 ml IM dose) can be offered to children aged 6 months to 4 years. The National Advisory Committee on Immunization (NACI) published *Recommendations on the use of Pfizer-BioNTech Comirnaty (3mcg) COVID-19 vaccine in children 6 months to 4 years of age* at <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-pfizer-biontech-comirnaty-3-mcg-covid-19-vaccine-children-6-months-4-years.pdf> on October 21, 2022.

Scheduling of Pfizer BioNTech's monovalent COMIRNATY® 6 months – 4 years vaccine

Scheduling	Immune competent child	Moderately to severely immunocompromised child
Dose 1	Can be administered at the same time as other vaccines, refer to bullet 3.	
Dose 2	8 weeks later (min. 21 days only between doses 1 and 2)	4-8 weeks later (min. 21 days only between doses 1 and 2)
Dose 3	8 weeks later	4-8 weeks later
Dose 4	N/A	4-8 weeks later

Notes

1. A parent/legal guardian must be present to provide verbal informed consent for COVID-19 immunization for a young child. If the parent chooses an adult designate (e.g. grandparent, aunt) to accompany the child for immunization, a consent form signed by the parent/guardian must be presented to the immunizer.
2. **mRNA COVID-19 vaccine series for young children require a different number of doses.** Therefore, children who receive a mixed Moderna-Pfizer series are recommended by NACI to complete a series with the number of doses as per the Pfizer BioNTech schedule shown above. **Either age-appropriate mRNA vaccine can be used to complete the initial series of a mixed schedule.**

3. A 14-day interval between administration of COVID-19 vaccines and other vaccines is preferred for young children per NACI guidelines. However, similar to other COVID-19 vaccines **in Saskatchewan, co-administration of COVID-19 vaccine and other vaccines on an individual basis is allowed to avoid missed opportunities.**
4. For those 6 months to 4 years of age who are moderately to severely immunocompromised, a 3-dose primary series of Moderna Spikevax vaccine (25 mcg) is preferred. However, a mixed schedule with Pfizer-BioNtech requires a total of 4 doses and therefore, either product can be used to complete the initial series.
5. For those children 6 months to 4 years previously infected with COVID-19, NACI recommends an 8-week interval after symptom onset or a positive test if asymptomatic. For children who are moderately to severely immunocompromised this interval may be shortened to 4 weeks. Upon parent request children may be provided the vaccine once their symptoms have improved.
6. **If a child transitions from 4 years old to 5 years old while receiving an initial Pfizer BioNTech Comirnaty series, it is recommended that they should receive the appropriate dose for their current age and follow the initial series schedule based on the age that they started the series. See tables below for possible scenarios.**


Pfizer Dosage	Scenario 1A	Scenario 1B
Dose 1 3 mcg given	Was given at 4 years old	Was given at 4 years old
Age transition	Child turns 5 years of age following dose 1	Child turns 5 years of age following dose 1 and is moderately to severely immunocompromised
Dose 2 Give 10 mcg	8 weeks after dose 1 (min. 21 days only between doses 1 and 2)	4-8 weeks after dose 1 (min. 21 days only between doses 1 and 2)
Dose 3 Give 10 mcg	8 weeks later	4-8 weeks later
Dose 4 give 10 mcg	N/A	4-8 weeks later

Pfizer Dosage	Scenario 2A	Scenario 2B
Dose 1 3 mcg given	Was given at 4 years old	Was given at 4 years old
Dose 2 3 mcg given	Was given at 4 years old	Was given at 4 years old
Age transition	Child turns 5 years of age following dose 2	Child turns 5 years of age following dose 2 and is moderately to severely immunocompromised
Dose 3 Give 10 mcg	8 weeks later	4-8 weeks later
Dose 4 Give 10 mcg	N/A	4-8 weeks later

The following documents are recommended for review and reference:

1. Pfizer BioNTech's monovalent COMIRNATY® 6 months – 4 years vaccine fact sheet, screening questions and aftercare sheet (<https://www.saskatchewan.ca/government/health-care-administration-and-provider-resources/treatment-procedures-and-guidelines/emerging-public-health-issues/2019-novel-coronavirus/covid-19-vaccine/covid-19-vaccine-information/covid-19-vaccine-details>)
2. Pfizer BioNTech's monovalent COMIRNATY® 6 months – 4 years pages in the *Saskatchewan Immunization Manual* (<https://www.ehealthsask.ca/services/Manuals/Documents/sim-chapter10.pdf>).
3. *The COVID-19 Vaccine Contraindications and Precautions Background Document* Table 4 (<https://www.ehealthsask.ca/services/Manuals/Documents/COVID-19-Vaccine-Contraindications-and-Precautions-Background-Document.pdf>).

Sincerely,



Dr. Saqib Shahab
Chief Medical Health Officer

cc: Saskatchewan Medical Health Officers